Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation.
about
Tamoxifen regulation of sphingolipid metabolism--Therapeutic implicationsReversal effect of ST6GAL 1 on multidrug resistance in human leukemia by regulating the PI3K/Akt pathway and the expression of P-gp and MRP1Dynamics of ceramide generation and metabolism in response to fenretinide--Diversity within and among leukemiaThe impact of sphingosine kinase-1 in head and neck cancer.Ceramide glycosylation catalyzed by glucosylceramide synthase and cancer drug resistance.Interdiction of sphingolipid metabolism to improve standard cancer therapies.Inhibition of ceramide metabolism sensitizes human leukemia cells to inhibition of BCL2-like proteinsCeramide kinase promotes tumor cell survival and mammary tumor recurrence.Lactosylceramide Mediates the Expression of Adhesion Molecules in TNF-α and IFNγ-stimulated Primary Cultured Astrocytes.Phosphorylation of serine palmitoyltransferase long chain-1 (SPTLC1) on tyrosine 164 inhibits its activity and promotes cell survival.B4GALT family mediates the multidrug resistance of human leukemia cells by regulating the hedgehog pathway and the expression of p-glycoprotein and multidrug resistance-associated protein 1Novel chemotherapeutic drugs in sphingolipid cancer research.Therapeutic potential of targeting ceramide/glucosylceramide pathway in cancer.Changes in molecular biology of chronic myeloid leukemia in tyrosine kinase inhibitor era.Role of Sphingolipids and Metabolizing Enzymes in Hematological Malignancies.Major apoptotic mechanisms and genes involved in apoptosis.A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.Apoptotic effects of non-edible parts of Punica granatum on human multiple myeloma cells.A Novel Natural Product, KL-21, Inhibits Proliferation and Induces Apoptosis in Chronic Lymphocytic Leukemia Cells.Mechanisms responsible for nilotinib resistance in human chronic myeloid leukemia cells and reversal of resistance.Translational Aspects of Sphingolipid Metabolism in Renal Disorders.Sphingolipid pathway enzymes modulate cell fate and immune responses.Aneuploid Cell Survival Relies upon Sphingolipid Homeostasis.Gaucher disease and chronic myeloid leukemia: first reported patient receiving enzyme replacement and tyrosine kinase inhibitor therapies simultaneously.Therapeutic potential of apigenin, a plant flavonoid, for imatinib-sensitive and resistant chronic myeloid leukemia cells.
P2860
Q28084270-16C96A6E-6736-4849-B7D0-5A3D4EAF6002Q28538781-39556BB2-8701-46B7-8831-096ECAC33985Q30278944-2525DB0C-8BE6-4BC7-97BE-1C5AFCB1511EQ33649748-201309B6-8E75-4A6E-9D10-44534A706386Q33733991-5D269CD8-5036-426A-BA19-4F46B2A98831Q34373466-D9939EE0-69F3-4062-A3F2-71458C4F48ABQ34559507-2FEDF53C-6FF0-4211-8774-70DF62721EDFQ34846801-9E20AC0F-989D-4BF0-B65A-C45C25485DACQ35569335-C72813B7-0393-468D-8EEB-0019A22B4E85Q36928954-0D45E7FF-24A2-49F1-94F2-96098F25A815Q36973762-E2CA9DD6-7750-4DDA-BAEC-76E9A4AE3904Q37721276-69EE2C35-6D37-4025-A301-B4CEAD909F0FQ38052818-FC7B70A9-5137-45C6-9F6A-91AD2AC65F43Q38133575-4ABA8841-07D9-4950-82CB-3FD5636BED87Q38495744-525E24AA-759C-44F4-82CF-2A44CD86F70CQ38802454-6D2428DB-F45B-4C4D-ADAF-D6EE16030CBBQ38835059-1667B1D3-2F98-4D8F-8C11-F2A2D8EB46A3Q38839835-160093A0-720A-4FCF-BAFD-288E3C749A36Q38840067-0E133F92-7D47-40EE-B631-FE872A3C777AQ39253571-31139B31-E950-402B-8654-AD21E8C2B859Q49399657-F560002E-1C9C-4B9E-AC80-E991D8929BEDQ50079745-29C2E49A-BBBB-452A-B3AD-676452631B94Q51813863-BCA94B7A-2F3C-456F-9059-2BCC7A51EC00Q54111080-E149EEDB-FEAC-4076-9078-EE8ABFBFBCBCQ54364714-B15682A1-5B59-4A13-B9E1-CBCD6F4936A2
P2860
Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Targeting glucosylceramide syn ...... ogenous ceramide accumulation.
@en
Targeting glucosylceramide syn ...... ogenous ceramide accumulation.
@nl
type
label
Targeting glucosylceramide syn ...... ogenous ceramide accumulation.
@en
Targeting glucosylceramide syn ...... ogenous ceramide accumulation.
@nl
prefLabel
Targeting glucosylceramide syn ...... ogenous ceramide accumulation.
@en
Targeting glucosylceramide syn ...... ogenous ceramide accumulation.
@nl
P2093
P2860
P1476
Targeting glucosylceramide syn ...... ogenous ceramide accumulation.
@en
P2093
Besim Ogretmen
Jacek Bielawski
Ufuk Gunduz
P2860
P2888
P304
P356
10.1007/S00432-011-1016-Y
P50
P577
2011-08-11T00:00:00Z